Hoku's Commercialization Strategy Seen On Target (HOKU)

by: Mark Anderson

Hoku Scientific, Inc. (HOKU) maintained an "outperform" rating and $12 target price from a Piper Jaffray analyst:

"Hoku will continue to record substantial revenue growth driven by accelerated technology development in preparation for commercial markets," Piper analyst Jesse W. Pichel wrote in a recent report. [ more ]

I'm still waiting for Marketocracy to add this ticker to the stock universe so I can buy it for the mutual fund. If I had additional money in my personal portfolio, I would purchase more at this level.


Related:

« Any opinions expressed on the Seeking Alpha sites are those of the individual authors and do not necessarily represent the opinion of Seeking Alpha or its management. »

About this article:

Expand
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here